Inhibrx LP:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Inhibrx LP - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10687
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Inhibrx LP (Inhibrx) is a biotherapeutic company that develops drugs for treatment of oncology, infectious disease and inflammatory diseases. The company’s products include therapeutic proteins with multivalent and multi specific molecules which are designed from their antibody technology. Its programs are based on comprehensive target discovery and selection expertise with its creative implementation for therapeutic research. The company’s proprietary platforms enable fit-for-function biotherapeutics that interface with the biology of each target antigen and focus immune activation and mediate enhanced signalling. It also develops proprietary discovery and optimization platforms for conventional and single domain antibodies. Inhibrx is headquartered in La Jolla, California, the US.

Inhibrx LP – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Inhibrx LP, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Inhibrx LP, Medical Devices Deals, 2012 to YTD 2018 9
Inhibrx LP, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Inhibrx LP, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Inhibrx Raises USD410 Million in Venture Financing 11
Inhibrx Secures USD20 Million from Oxford Finance 12
Partnerships 13
Inhibrx and Alpha-1 Project Enter into Agreement 13
Licensing Agreements 14
Inhibrx Enters into Licensing Agreement with Celgene 14
Equity Offering 15
Inhibrx to Raise Funds through Private Placement of Shares 15
Inhibrx LP – Key Competitors 16
Inhibrx LP – Key Employees 17
Inhibrx LP – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Clinical Trials 19
Oct 31, 2017: Inhibrx Wins CARB-X Award Of Up To $6.0M To Accelerate Development Of Its Novel Antibody, INBRX-111, To Treat Pseudomonas Infections 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Inhibrx LP, Pharmaceuticals & Healthcare, Key Facts 2
Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Inhibrx LP, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Inhibrx LP, Deals By Therapy Area, 2012 to YTD 2018 8
Inhibrx LP, Medical Devices Deals, 2012 to YTD 2018 9
Inhibrx LP, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Inhibrx Raises USD410 Million in Venture Financing 11
Inhibrx Secures USD20 Million from Oxford Finance 12
Inhibrx and Alpha-1 Project Enter into Agreement 13
Inhibrx Enters into Licensing Agreement with Celgene 14
Inhibrx to Raise Funds through Private Placement of Shares 15
Inhibrx LP, Key Competitors 16
Inhibrx LP, Key Employees 17

List of Figures
Inhibrx LP, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Inhibrx LP, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Inhibrx LP, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Inhibrx LP, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Inhibrx LP:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TPF SA:企業の戦略的SWOT分析
    TPF SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • JBS S.A.:戦略・SWOT・企業財務分析
    JBS S.A. - Strategy, SWOT and Corporate Finance Report Summary JBS S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Carmanah Technologies Corporation:企業の戦略的SWOT分析
    Carmanah Technologies Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Pacific & Orient Berhad:企業の戦略・SWOT・財務情報
    Pacific & Orient Berhad - Strategy, SWOT and Corporate Finance Report Summary Pacific & Orient Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • ethris GmbH-製薬・医療分野:企業M&A・提携分析
    Summary ethris GmbH (Ethris) is a biotechnology company that develops and manufactures therapeutics. The company develops therapeutics based on its proprietary platform technologies. It uses technologies including magnetovax and SNIM RNA. Ethris’ magnetovax is a platform for personalized tumor vacci …
  • Covance Inc:企業の戦略的SWOT分析
    Covance Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Knoll Inc (KNL):企業の財務・戦略的SWOT分析
    Knoll Inc (KNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • University of Maryland Medical Center Corp:企業の戦略的SWOT分析
    University of Maryland Medical Center Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • Revolution Medicines Inc-製薬・医療分野:企業M&A・提携分析
    Summary Revolution Medicines Inc (Revolution Medicines) is a drug discovery company with focus on the development of therapies for cancer. The company’s programs include SHP2 Program and mTOR Program. Its REVBLOCKS platform, an integrated suite of modular synthesis methodologies, facilitates the pro …
  • Sanovas Inc-医療機器分野:企業M&A・提携分析
    Summary Sanovas Inc (Sanovas) focuses on the development of minimally invasive diagnostic and therapeutic technologies and solutions. The company provides imaging technologies, interventional lung, interventional ENT, and interventional uro and gyn products. Its imaging technologies product provides …
  • Suncor Energy Inc (SU):電力:M&Aディール及び事業提携情報
    Summary Suncor Energy Inc. (Suncor) is an integrated energy company that mainly focuses on the development of Athabasca oil sands. It carries out development and up gradation of oil sands; offshore and onshore oil and gas production; refining of crude oil and marketing of petroleum and petrochemical …
  • Imbed Biosciences Inc:医療機器:M&Aディール及び事業提携情報
    Summary Imbed Biosciences Inc (Imbed) is a medical device company that develops technologies for imbedding bioactive molecules in wound dressings and surgical implants. The company’s polymeric microfilm product platform develops bioactive molecules on tissue surfaces to manage wound infections, biof …
  • Acacia Mining Plc:企業の戦略・SWOT・財務情報
    Acacia Mining Plc - Strategy, SWOT and Corporate Finance Report Summary Acacia Mining Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • City Developments Ltd:戦略・SWOT・企業財務分析
    City Developments Ltd - Strategy, SWOT and Corporate Finance Report Summary City Developments Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Lancer Systems L.P.:企業の戦略・SWOT・財務情報
    Lancer Systems L.P. - Strategy, SWOT and Corporate Finance Report Summary Lancer Systems L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Lumosa Therapeutics Co Ltd (6535):製薬・医療:M&Aディール及び事業提携情報
    Summary Lumosa Therapeutics Co Ltd (Lumosa Therapeutics) is a developer of drugs for the treatment of neurological and inflammatory diseases. The company’s pipeline products include LT-1001, an analgesic injection for severe pain relief; and LT-3001, a novel small molecule for acute ischemic stroke. …
  • CellProthera-製薬・医療分野:企業M&A・提携分析
    Summary CellProthera (CellProthera) focuses on the development of therapeutic solutions for the regeneration of organs which are damaged by disease or trauma from autologous blood peripheral stem cells. The company’s lead candidate ProtheraCytes, is an advanced therapy medicinal product within tissu …
  • Swiss Re Group:企業の戦略・SWOT・財務情報
    Swiss Re Group - Strategy, SWOT and Corporate Finance Report Summary Swiss Re Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Southwestern Energy Co (SWN):石油・ガス:M&Aディール及び事業提携情報
    Summary Southwestern Energy Co (Southwestern Energy) is an oil and gas company that carries out exploration, development and production of natural gas and crude oil. The company operates through its divisions such as exploration, drilling, completion, production and midstream. Its midstream business …
  • Levi Strauss & Co (LEVI):企業の財務・戦略的SWOT分析
    Levi Strauss & Co (LEVI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆